Skip to content
FrontierPicks

Covered

MRX · Marex Group

Conviction · Low · more likely to lag the S&P 500 over the next three months

Wrong if: a daily close above $81.32

Note written ·

Price against the kill line

13.0% clear of its kill line on the 13 November 2026 close.

How to read this

This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.

The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.

The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides

MRXMarex Group
$81.32
$70.72
13.0%well clear

Three months against the kill line

MRX daily closes from 17 August 2026 to 13 November 2026, last $70.72, against its kill line: a daily close above $81.32. 17 August 2026: $71.2918 August 2026: $71.7219 August 2026: $70.0420 August 2026: $69.4421 August 2026: $72.8324 August 2026: $70.5425 August 2026: $70.8526 August 2026: $72.1227 August 2026: $71.3828 August 2026: $72.8431 August 2026: $72.481 September 2026: $72.622 September 2026: $71.673 September 2026: $75.654 September 2026: $78.278 September 2026: $76.719 September 2026: $75.7210 September 2026: $74.0911 September 2026: $73.0014 September 2026: $70.8215 September 2026: $68.4016 September 2026: $72.3817 September 2026: $73.2718 September 2026: $74.3921 September 2026: $75.7122 September 2026: $72.6523 September 2026: $71.5924 September 2026: $72.6925 September 2026: $71.3128 September 2026: $71.2929 September 2026: $72.1330 September 2026: $69.761 October 2026: $70.962 October 2026: $72.755 October 2026: $75.216 October 2026: $74.247 October 2026: $71.888 October 2026: $71.179 October 2026: $71.9212 October 2026: $72.2913 October 2026: $71.9514 October 2026: $69.3815 October 2026: $72.3016 October 2026: $70.5019 October 2026: $69.6520 October 2026: $70.4721 October 2026: $71.5422 October 2026: $68.5423 October 2026: $69.9626 October 2026: $70.7327 October 2026: $69.5028 October 2026: $66.2829 October 2026: $65.0530 October 2026: $64.412 November 2026: $64.903 November 2026: $68.384 November 2026: $70.345 November 2026: $64.966 November 2026: $66.189 November 2026: $67.9110 November 2026: $69.2611 November 2026: $73.9312 November 2026: $71.6813 November 2026: $70.72

Daily closes, to . Red: the kill line, a daily close above $81.32, on record since 11 November 2026. The shares are down 0.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.

Kill line

A daily close above $81.32, over the 52-week high of $79.11, which would show the shares leading the S&P 500 again. A raised 2027 adjusted profit growth target above the current 10% to 20% would also show it.

Research onlyNot in the portfolio.

The portfolio's record →

Key figures from the filings · Financials

Filed figures are not available: no quarterly report in US GAAP with the SEC (a foreign filer reports on Form 20-F or 40-F).

All filed numbers

What Marex Group reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .

Short interest (FINRA, settled 15 October 2026, published 26 October 2026): the share of shares outstanding is not available, 3.5 days of average trading to cover, −7.6% since the previous report.

Insiders' open-market trades SEC Form 4, by trade date, to
Window Bought Sold
90 daysfrom $0 $7.2M
12 monthsfrom $0 $19.8M

The thesis

Marex Group's profit is growing fast, but the shares are more likely to lag the S&P 500 than lead it over three months. The third-quarter adjusted margin of 23.7% came in under the second quarter's 23.8%, and net interest income fell, so the margin test failed even in a record quarter. The fourth-quarter report, estimated for early 2027, settles whether margin and interest income turn up.

The shares fell to a close of $64.96 on 5 November 2026, the day of the report. They then closed at $66.18 on 6 November 2026, $67.91 on 9 November 2026, $69.26 on 10 November 2026 and $73.93 on 11 November 2026. That last close is above the $70.34 close of 4 November 2026, the session before the report, and above the 50-day average of $71.16. The market has therefore priced the report's drop out. It sits 6.5% below the 52-week high of $79.11 (intraday, 8 September 2026), with management's 2027 target of 10% to 20% adjusted profit growth set against 63% growth in the first nine months of 2026.

Bullish and bearish views on Marex Group plc

The bull case on Marex Group plc (MRX), in brief: third-quarter results were a record. The bear case: margin missed its own prior level.

Bull case

  • Third-quarter results were a record. The 5 November 2026 release reported revenue of $743.2 million, up 53%, and adjusted profit before tax (PBT) of $176.1 million, up 75%. Adjusted return on equity was 35.7%, against 27.6% a year earlier.
  • Results beat analyst estimates. Benzinga reported on 5 November 2026 that adjusted earnings per share of $1.67 beat the $1.53 estimate. Sales of $743.2 million beat the $684.065 million estimate.
  • Margin is far above last year. The adjusted margin of 23.7% compares with 20.7% a year earlier, per the release. Management still sees a path to 30%, though it expects slower improvement than in 2026, per a TradingKey summary of the 5 November 2026 call.
  • Management backed its 2027 target. The release cites confidence in 10% to 20% adjusted PBT growth in 2027. On the call, management said October matched the year-to-date average, per TradingKey.
  • Analysts moved targets up after the report. Barclays kept its Overweight rating and raised its target to $95 on 6 November 2026, per a news report of the note. MarketBeat listed a consensus target of $83.38 on 6 November 2026.
  • More acquisitions are in negotiation. Management said on 5 November 2026 that four deals have agreed commercial terms, with signings expected in the fourth quarter of 2026 or the first quarter of 2027, per TradingKey. It estimates close to $300 million of deployable capital while staying investment grade.

Bear case

  • Margin missed its own prior level. The 23.7% third-quarter figure is below the second quarter's 23.8%, per the company's 5 November 2026 and 12 August 2026 releases. Profit rose 6% from the second quarter, per TradingKey, while revenue rose 53% from a year earlier.
  • Interest income keeps shrinking. Net interest income was $35.7 million in the third quarter, down 7%, and $106.3 million over nine months, down 16%, per the release. One analyst on the 5 November 2026 call called the quarter lighter than expected, and management cited higher funding costs, per TradingKey.
  • Metals drove the fastest growth. Market Making revenue was $151 million, including $91 million from metals, and its adjusted PBT reached $58 million against $7 million a year earlier, per TradingKey. Trading conditions set much of that line.
  • Prime growth should slow. Prime revenue was about $115 million, double the year-earlier level, per the release. Management does not expect that pace to repeat, because balance-sheet growth consumes capital, per the call summary.
  • The near-term message is flat. Management expects operations to stay around current levels, subject to the normal Christmas slowdown, per TradingKey. Material contribution from pending acquisitions is unlikely before the second half of 2027.
  • Insiders sold into the recovery and the decline. President Simon Van Den Born sold 22,456 shares at an average $66.29 on 5 November 2026 and 15,272 shares at an average $72.04 on 12 October 2026, both under Rule 10b5-1 plans, per SEC Form 4 filings. Paolo Tonucci sold 16,666 shares at an average $72.03 on 12 October 2026, also under a plan.

Price setup

The last close was $73.93 on 11 November 2026. The 50-day average is $71.16 and the 200-day average is $58.09, both from adjusted daily closes. The shares are up 2.4% over three months, from an adjusted close of $72.20 on 13 August 2026.

The 5 November 2026 close of $64.96 is the low of the post-report drop. The close of $70.34 on 4 November 2026 was the pre-report level and has been retaken. Above the price, the 52-week intraday high of $79.11 on 8 September 2026 is the next marker. Below it, the 200-day average of $58.09 sits well under the current price. The 52-week closing low was $31.82 on 20 November 2025.

Legacy investors Helikon, CVC and BXC still hold stock they could place without a scheduled date. A placement into a stronger share price would add supply near the September high.

Catalysts ahead

  • Q4 2026 to Q1 2027 (est.): Expected signing of some of the four acquisitions with agreed commercial terms. Signed deals would show whether the acquisition pace continues, though material earnings contribution is unlikely before the second half of 2027.
  • ~early 2027 (est.): Expected completion of the Bright Point International clearing acquisition. Completion would strengthen Clearing in Asia and feed the full-year effects included in the 2027 profit target.
  • ~Q1 2027 (est.): Fourth-quarter 2026 results; the company has not announced a date. The report tests margin against the 23.7% third-quarter figure, net interest income against $35.7m, and the starting point for the 2027 growth target.

What would change the view

A daily close above $81.32, over the 52-week high of $79.11, which would show the shares leading the S&P 500 again. A raised 2027 adjusted profit growth target above the current 10% to 20% would also show it.

What it trades with

The shares respond to company-specific earnings more than to any single market theme, and the 5 November 2026 fall followed the company's own report. Three outside drivers show up in the third-quarter numbers. Metals trading conditions fed $91 million of Market Making revenue. Federal funds rates moved net interest income, which rose $6 million from the second quarter mainly on a 0.10 percentage-point higher average rate, per the call summary. Equity market swings matter at the margin: levered exchange-traded fund balances softened in the AI-stock sell-off but stayed relatively stable, per the same summary.

The evidence, claim by claim (8)
  1. Q3 2026 revenue was $743.2m, up 53%; adjusted profit before tax was $176.1m, up 75%; adjusted margin was 23.7% against 20.7% a year earlier. Marex Q3 2026 results release (GlobeNewswire) · as of
  2. Q3 adjusted EPS of $1.67 beat the $1.53 estimate; sales of $743.2m beat the $684.065m estimate. Benzinga · as of
  3. Q3 net interest income was $35.7m, down 7%; nine-month net interest income was $106.3m, down 16%. Marex Q3 2026 results release (GlobeNewswire) · as of
  4. Nine-month 2026 adjusted profit before tax was $494.7m, up 63%, at a 23.2% adjusted margin. Marex Q3 2026 results release (GlobeNewswire) · as of
  5. Management remained comfortable with 10% to 20% adjusted profit before tax growth in 2027 and said October matched the year-to-date average. TradingKey summary of Q3 2026 earnings call · as of
  6. Market Making revenue was $151m, including $91m from metals; segment adjusted profit before tax was $58m against $7m a year earlier. TradingKey summary of Q3 2026 earnings call · as of
  7. Barclays maintained Overweight on Marex Group and raised its price target to $95. Barclays note, reported in company news · as of
  8. President Simon Van Den Born sold 22,456 shares at an average $66.29 on 5 November 2026 under a Rule 10b5-1 plan. SEC Form 4, filed 9 November 2026 · as of

Sources

Related · shared themes

Every buy and sale, with its reason, is published in the portfolio feed. Follow the portfolio feed → Follow @frontierpicks on X